Questionnaire and Laboratory Data on Vitiligo Vulgaris

Vitiligo Vulgaris Clinical Trial

Official title:

Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01206374
• Other study ID #: 10-027SLRHC
• Status: Completed
• Phase: N/A
• First received: September 20, 2010
• Last updated: May 22, 2015
• Start date: August 2010
• Est. completion date: September 2014

Study information

• Verified date: May 2015
• Source: St. Luke's-Roosevelt Hospital Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.

Description:

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: September 2014
• Est. primary completion date: October 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of Vitiligo Vulgaris

• Ability to sign consent

Exclusion Criteria:

• Pregnant

• Inability to sign consent

• Inability to complete questionnaire

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Vitiligo
• Vitiligo Vulgaris

Locations

Country	Name	City	State
United States	Department of Dermatology, Beth Israel Medical Center	New York	New York
United States	Department of Dermatology, St. Luke's-Roosevelt Hospital Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
St. Luke's-Roosevelt Hospital Center	Beth Israel Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (3)

Pagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008 Jun;81(6):463-6. — View Citation

Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010 Jun;62(6):937-41. doi: 10.1016/j.jaad.2009.11.024. — View Citation

Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010 Aug;22(4):445-52. doi: 10.1097/MOP.0b013e32833b6ac3. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of life disturbances in people with vitiligo	dermatology life quality indices were you used and correlated with location of disease	point prevalence	No
Secondary	self-reporting of vitiligo disease symptoms and history	Correlation of the patient survey response with chart documentation was performed.	single survey	No